Wednesday, February 1, 2023
HomeHealthHuman trials of Bharat Biotech's Covid vaccine Covaxin begin in Rohtak

Human trials of Bharat Biotech’s Covid vaccine Covaxin begin in Rohtak

Haryana Health Minister Anil Vij said the trials have begun at Rohtak's Post-Graduate Institute of Medical Sciences, and the first 3 subjects have 'tolerated' the vaccine well.

Text Size:

Chandigarh: The human trial of Bharat Biotech’s anti-COVID-19 vaccine Covaxin began at Rohtak’s Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij tweeted.

Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak today, Vij, who is also the Home and Science & Technology minister said.

Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects, Vij further said in his tweet.

Bharat Biotech got the country’s drug regulator’s approval to start clinical trials of its anti-Corona vaccine Covaxin recently.

There are over seven anti-corona vaccines at various stages of development in the country with two of them having received the drug regulator’s go-ahead to start the human clinical trials of their vaccines.

Earlier this month, Zydus had said it has received approval from authorities to start human trials for its anti-COVID-19 vaccine.

Also read: Why the fight over a coronavirus vaccine will be intense, irrational and even nasty


Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism


  1. Is not The print run by darbari Mr Coup-ta who lied and ranted about an intended military coup? Poor fellow’s sponsors are going away? Thats why he is begging around for money? No discerning reader will pay to keep alive yellow rags

Comments are closed.

Most Popular